How Many People Take Statins in the U.S. and Beyond

Roughly 92 million adults in the United States reported taking a statin during the 2018–2019 period, representing about 35% of the adult population. That figure reflects a nearly threefold increase from about 31 million users a decade earlier. But the story behind those numbers is layered: who gets prescribed statins, who actually fills the prescription, and who keeps taking them are three very different questions, and the answers change depending on sex, race, income, and geography.

How U.S. Statin Use Has Grown

The rise has been dramatic. Between 2008–2009 and 2018–2019, the number of Americans reporting statin use climbed from about 31 million to 92 million, a roughly 197% increase. Annual statin prescriptions grew from 461 million to 818 million during the same window.¹ Much of that acceleration happened after 2013, when the American College of Cardiology and American Heart Association released updated cholesterol guidelines that broadened who should be considered for statin therapy. The sharpest single jump came in the 2018–2019 reporting period.

Interestingly, later guideline revisions pulled back on the scope of who would be recommended a statin. Applying the 2018 cholesterol guideline to national survey data suggests that about 46 million adults, or roughly 20%, would be recommended statin use under those newer criteria, down from about 78 million under the 2013 guideline.² So the guidelines expanded the pool of eligible patients and then partially contracted it, but actual usage kept climbing regardless. Real-world prescribing habits tend to lag behind guideline shifts by years, and the overall cultural normalization of statin therapy seems to have its own momentum.

Who Is Actually Taking Statins

Among adults who meet primary prevention criteria (meaning they have no established heart disease but carry elevated cardiovascular risk), about one in four reported using a statin in nationally representative U.S. survey data. The prevalence was roughly 25.5% in that eligible group, with a mean age around 62 and a strong male skew: about 62% of users were men.³

Age matters a great deal. Among younger adults aged 18 to 44, statin use rose from about 2.5% in 1999 to roughly 8% by 2020, but the increase was slow and not statistically significant as a trend.⁴ This makes sense: younger adults are less likely to carry the ten-year cardiovascular risk thresholds that trigger a statin recommendation under current guidelines. The bulk of statin users are middle-aged and older.

Sex Gaps in Prescribing

Women consistently use statins at lower rates than men, and the gap is not fully explained by differences in risk profiles. In a large U.S. registry of nearly 5,700 adults eligible for guideline-recommended statin therapy, 67% of women were prescribed any statin compared with 78% of men. Women were also less likely to receive the recommended intensity. When researchers adjusted for demographics, clinical characteristics, patient beliefs, and provider characteristics, the gap persisted: women had about 30% lower odds of being on a statin at all.⁵

Part of this gap reflects supply-side factors. Women were more likely to report never having been offered a statin in the first place. But demand-side factors also play a role: women were roughly twice as likely to have declined statin therapy and nearly twice as likely to have discontinued it. Among patients with known coronary artery disease, women who were started on guideline-directed statin therapy still faced higher rates of heart attack, stroke, and death compared with men on the same regimen, suggesting they may also be started later in their disease course or face other treatment-related disparities.⁶

Racial and Ethnic Disparities

The disparities run deep. A nationally representative cross-sectional analysis found that Black men had significantly lower statin use for both primary and secondary prevention, even after adjusting for disease severity and structural factors. Hispanic women showed similar shortfalls. For secondary prevention, where the evidence for statin benefit is strongest, the gap extended to non-Hispanic White women, non-Hispanic Black women, and Mexican American women.⁷

What drives these gaps? A mediation analysis that dug into the mechanisms found that when Hispanic, Black, and other minority patients had the same financial resources, access to care, and quality of care as White patients, the direct racial difference in statin use largely disappeared. The disparities were driven primarily through indirect pathways: differences in insurance coverage, income, and healthcare access that track with race in the United States.⁸ In other words, the problem is less about race per se and more about the economic and structural disadvantages that correlate with it.

New risk calculators may also affect who gets flagged for treatment. The recently introduced PREVENT equations, which replaced the older pooled cohort equations for estimating cardiovascular risk, substantially reduced the number of people eligible for statins. One analysis of over 36,000 patients not already on statins found that PREVENT cut statin eligibility by about 78%, with the largest reductions among women, younger adults, and Black patients.⁹ Whether this better targets treatment or inadvertently widens existing disparities is an active debate in cardiology.

The Global Picture

Statin use varies enormously across the world. In 2020, North America led globally, followed by Europe. Latin America, the Middle East, East Asia, and sub-Saharan Africa trailed far behind. Between 2015 and 2020, statin use grew in both high-income and low- and middle-income countries, but the gap remained massive: by 2020, high-income countries used statins at roughly seven times the rate of lower-income nations.¹⁰

Even within income groups, the variation is striking. Among high-income countries, Denmark, Canada, and the UK had the highest utilization, while Japan, Chile, and Kuwait had some of the lowest. Several middle-income countries bucked the trend: Lebanon, Algeria, Brazil, Thailand, and South Africa all had statin use above the global average. Meanwhile, some of the world’s most populous nations, including China, India, Indonesia, Pakistan, Bangladesh, and Mexico, fell well below it.

In 41 low- and middle-income countries studied individually, only about 8% of people who should have been on a statin for primary prevention were actually taking one. For secondary prevention, meaning people who already had cardiovascular disease, the rate was still just 22%. No region or income group met the World Health Organization’s target that at least 50% of eligible people receive statin therapy.¹¹

Why Statins Remain Scarce in Poorer Countries

Affordability is the dominant barrier. In low-income countries, statins can cost around six days’ wages per month. In rural areas of the poorest countries, statins have been estimated to eat up nearly half of a household’s discretionary income.¹² Even where generic versions exist, procurement and distribution systems often fail to get them to patients. In public health facilities across lower-income countries, the median availability of generic statins was just 5.4%, meaning most government-run pharmacies simply did not stock them. Private facilities did somewhat better, at roughly 36% availability, but at higher prices.¹³

Health spending at the national level also strongly predicts statin use. Countries that spend less on healthcare overall tend to have lower statin utilization, regardless of their disease burden. Within those countries, individuals who are wealthier, more educated, older, and living in urban areas are more likely to be on a statin, compounding the inequity.

Many People Who Start Statins Eventually Stop

Getting a prescription is only half the battle. In a large U.S. registry, about 27% of adults eligible for statins were not on treatment. Of those, roughly 59% said they had never been offered a statin, about 10% had been offered one and declined, and 31% had started but discontinued.¹⁴

Discontinuation rates are higher for people taking statins for primary prevention than for those who have already had a heart attack or other cardiovascular event. A large UK primary care study found that 47% of primary prevention patients stopped their statin over a median follow-up of about two and a half years, compared with 41% of secondary prevention patients. About a quarter of primary prevention users had quit within the first year. The reassuring finding, though, is that most people who stop do eventually restart: about 72% of primary prevention patients and 75% of secondary prevention patients resumed their statin within two years of stopping.¹⁵

That stop-and-start pattern matters because intermittent use blunts the long-term cardiovascular benefit. A large Scandinavian study of nearly 290,000 new statin users confirmed that adherence was consistently lower in primary prevention: people who have never had a heart attack understandably feel less urgency about a daily pill.¹⁶

Side Effects, Real and Perceived

Side-effect concerns are the most commonly cited reason people give for stopping statins, and the line between real and perceived effects is blurrier than you might expect. Muscle aches are the most frequently reported complaint, but large placebo-controlled trials consistently show that muscle symptoms occur at similar rates in people taking a sugar pill. An analysis of statin adverse events reported to the FDA found that subjective side effects (pain, fatigue, cognitive symptoms) were reported far more often than objective ones (measurable lab abnormalities). Subjective complaints were also reported more frequently by women and more often in the United States than in other countries.¹⁷

This does not mean nobody has real muscle problems from statins. A small fraction of users genuinely do, and rare but serious events like rhabdomyolysis exist. But the evidence strongly suggests that widespread media coverage of statin side effects and word-of-mouth concern amplify the experience of symptoms, a phenomenon known as the nocebo effect: you feel worse because you expect to. For many people who quit a statin because of muscle aches, a trial of a different statin at a lower dose resolves the problem.

Statin Intensity and What It Means

Not all statin prescriptions are equal. Guidelines divide statins into low, moderate, and high intensity, based on how much they lower LDL cholesterol. For patients with established cardiovascular disease, guidelines recommend high-intensity therapy. In practice, that recommendation is not always followed. A nationwide U.S. study of patients with confirmed atherosclerotic cardiovascular disease found that only about 22.5% were on a high-intensity statin, while roughly 28% were on a low- or moderate-intensity statin and about half were on no statin at all.¹⁸

That underuse matters clinically. In a large Veterans Affairs study of over 500,000 adults with cardiovascular disease, there was a graded relationship between statin intensity and survival. One-year mortality was 4.0% for high-intensity statin users, 4.8% for moderate-intensity users, 5.7% for low-intensity users, and 6.6% for those on no statin. After adjusting for the likelihood of being prescribed a high-intensity statin, high-intensity therapy was associated with about a 9% lower risk of death compared with moderate intensity. Among those already on high-intensity statins, patients on the maximum dose had an additional survival advantage over those on submaximal doses.¹⁹

Your Doctor’s Specialty Changes What You Get

Where you receive care is surprisingly predictive of whether you end up on a statin and at what dose. Cardiology practices had dramatically higher rates of guideline-recommended statin use than primary care settings. In one registry spanning 74 practices, the proportion of patients on guideline-intensity statins ranged from about 13% at the lowest-prescribing practices to over 71% at the highest. The top-prescribing practices were overwhelmingly cardiology offices.²⁰

Patients who saw a cardiologist were more likely to be on a statin, more likely to be on a high-intensity statin, and more adherent to their regimen compared with patients seen only by primary care. There was a dose-response pattern: more cardiology visits were associated with higher statin use and better adherence.²¹ This is not necessarily an argument that everyone needs a cardiologist. But it does suggest that the wide local-area variation in statin prescribing observed even among patients with the same diagnoses reflects provider beliefs and practice patterns as much as patient need.²²

The Generic Revolution and What It Did to Cost

Statins were once expensive brand-name medications. The arrival of generic versions transformed the market. When generic atorvastatin launched in 2011, its per-prescription cost was about $159. By 2022, it had fallen to around $10. Generic lovastatin showed a similar trajectory, dropping from about $130 per prescription at launch to $9.²³

At the national level, generic competition was associated with a roughly 91% reduction in annual spending on statins, translating to nearly $12 billion in annual savings for the U.S. healthcare system. For individual patients, the savings averaged about $926 per year. The reductions hit across all payer types: private insurance, Medicare, Medicaid, and out-of-pocket spending all dropped substantially.²⁴ This cost collapse is one reason statin use has continued expanding: a medication that once required meaningful financial commitment now costs less than a streaming subscription for most insured Americans.

Add-On Therapies for People Who Cannot Reach Their Goals

Some patients cannot tolerate statins at sufficient doses or do not achieve adequate cholesterol lowering on statins alone. Two classes of add-on drugs have emerged. Ezetimibe, a generic tablet, works through a different mechanism and, when added to a statin, has been shown to reduce heart attacks by about 13% and strokes by about 18%. PCSK9 inhibitors, which are injectable and much more expensive, offer somewhat larger reductions in those events. Neither class has been shown to significantly reduce overall mortality or cardiovascular death when added to a statin, at least in the trials conducted so far.²⁵ These agents are relevant to the usage picture because they are sometimes used as statin alternatives, meaning a small but growing number of people who would otherwise be counted among statin users are instead on non-statin lipid-lowering therapy.

Statins in Children

Statin prescribing in children is a much smaller but growing phenomenon, primarily limited to children with familial hypercholesterolemia, a genetic condition that causes dangerously high cholesterol from birth. Evidence from multiple studies shows statins effectively lower LDL cholesterol in children and appear to slow early indicators of artery thickening.²⁶ A Cochrane review found that statins reduced cholesterol at all measured time points with few identified safety concerns, though it noted that long-term safety data remain limited.²⁷ Despite the favorable short-term evidence, many eligible children are not receiving treatment. The reluctance is understandable: committing a child to decades of daily medication requires strong confidence in long-term safety that only time can fully provide.